A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
University of Oxford
Merck Sharp & Dohme LLC
University of Arizona
City of Hope Medical Center
Amgen
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Teikyo University
NYU Langone Health